The TSC Alliance is an internationally recognized non-profit organization that aims to improve the lives of people with tuberous sclerosis complex (TSC). TSC is a genetic disorder that causes tumours to form in many different organs, primarily in the brain, eyes, heart, kidney, skin and lungs. The aspects of TSC that most strongly impact quality of life are generally associated with the brain: seizures, developmental delay, intellectual disability and autism.
TSC Alliance’s aims are to drive research, improve quality care and access, and advocate for all affected by the disease. The TSC Alliance collaborates with individuals and families, along with the partnership of other organizations, fuelling their work to ensure people navigating TSC have support. touchNEUROLOGY had the pleasure of speaking with Kari Luther Rosbeck, President & Chief Executive Officer of TSC Alliance, to discuss main events that they have planned in the coming months and years.
Watch part 1 of the interview: TSC Alliance aims, objectives and initiatives for 2022/23
- Access more information about the TSC Alliance
- What is TSC?
- Information for healthcare professionals
- What events are planned in the coming months? (0:11)
Disclosures: Kari Rosenbeck has nothing to disclose in relation to this interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Rare Diseases
Lisa Sarfaty: Help support Rare Disease Day
Our society partner, NORD (The National Organization for Rare Disorder) has planned several initiatives to support this year’s Rare Disease Day on 28 February. These activities are aimed at raising awareness about rare diseases and the challenges faced by people living with these conditions. In this video, Lisa Sarfaty, NORD’s VP of Communication and Engagement, […]
Lisa Sarfaty: Exploring and addressing inequities in rare diseases
Rare diseases can present numerous challenges for those living with these conditions and the healthcare professionals caring for them. In this interview we discuss some of these with Lisa Sarfaty, VP of Communication and Engagement for NORD (The National Organization for Rare Disorders) and explore ways in which they could be tackled. Questions Could you […]
Francesco Saccà, EAN 2022: Improving quality of life for patients with generalized myasthenia gravis – ADAPT trial findings
The ADAPT trial (NCT03669588) supported US Food and Drug Administration approval of efgartigimod alfa-fcab in generalized myasthenia gravis. Dr Francesco Saccà (University of Naples Federico II, Naples, Italy) discussed the findings of the study, in terms of health-related quality-of-life outcomes. Questions: 1. What are the current challenges in managing cases of generalized myasthenia gravis? (00:14) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!